In the Aspire trial involving nearly 800 patients with multiple myeloma, those who took Amgen's Kyprolis coupled with standard treatment were found to live longer before their condition worsened.
In the Aspire trial involving nearly 800 patients with multiple myeloma, those who took Amgen's Kyprolis coupled with standard treatment were found to live longer before their condition worsened.
Share this Article
Recommended